Avon Radio Pharmaceuticals Solutions Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 07-12-2024
- Paid Up Capital ₹ 0.10 M
as on 07-12-2024
- Company Age 15 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 25614.29%
(FY 2022)
- Profit 2027644.00%
(FY 2022)
- Ebitda 5552.67%
(FY 2022)
- Net Worth 710.41%
(FY 2022)
- Total Assets 332.13%
(FY 2022)
About Avon Radio Pharmaceuticals Solutions
The Corporate was formerly known as Sudhansu Infotech Private Limited. The Company is engaged in the Information Technology Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Krishan Sharan, Vivek Aggarwal, and Ajit Sharan serve as directors at the Company.
- CIN/LLPIN
U93000DL2009PTC190896
- Company No.
190896
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Jun 2009
- Date of AGM
12 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
New Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Avon Radio Pharmaceuticals Solutions?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ajit Sharan  | Director | 23-Nov-2021 | Current |
| Krishan Sharan | Director | 23-Nov-2021 | Current |
| Vivek Aggarwal | Director | 04-Jun-2009 | Current |
Financial Performance of Avon Radio Pharmaceuticals Solutions.
Avon Radio Pharmaceuticals Solutions Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 25614.29% increase. The company also saw a substantial improvement in profitability, with a 2027644% increase in profit. The company's net worth Soared by an impressive increase of 710.41%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Avon Radio Pharmaceuticals Solutions?
In 2021, Avon Radio Pharmaceuticals Solutions had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sds Life Sciences Private LimitedActive 11 years 3 monthsKrishan Sharan and Ajit Sharan are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Avon Radio Pharmaceuticals Solutions?
Unlock and access historical data on people associated with Avon Radio Pharmaceuticals Solutions, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Avon Radio Pharmaceuticals Solutions, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Avon Radio Pharmaceuticals Solutions's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
